MiRNA-based therapy for Pulmonary arterial hypertension: MiRNA-22 protects against development of pulmonary arterial hypertension via down regulation of its target gene, 18/September/2014, 06.15 am

Insights into physiological mechanisms that inhibit the development of hyperglycemia and T2D: p63 increases CyclinD1 expression and inhibits gluconeogenesis via transcriptional regulation of Peroxisome proliferator-activated receptor γ coactivator-1α, 18/September/2014, 5.23 am
September 17, 2014
Insights into Why cancer patients should stay away from sugar-rich foods: High glucose increases the expression of a number of oncogenic Membrane receptors, and promotes metastaic invasion via down regulation of its target gene, 18/September/2014, 06.56 am
September 18, 2014
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, MiRNA-based therapy for Pulmonary arterial hypertension: MiRNA-22 protects against development of pulmonary arterial hypertension via down regulation of its target gene, 18/September/2014, 06.15 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: This study suggests that MiRNA-22by down regulating the expression of its target gene, it  may inhibit the development of pulmonary arterial hypertension.  Thus, pharmacological formulations encompassing “MiRNA-22 inhibitors” may be used to treat pulmonary arterial hypertension.

* Research cooperation

Comments are closed.